Oncology and Hematology

Episodes 33-48 of 438

Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
MinuteCE®
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
MinuteCE®
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
MinuteCE®
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
1.25 credits 9 episodes
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 credits 9 episodes
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Global Oncology Academy
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Global Oncology Academy
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
- Ryan Quigley
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Project Oncology®
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Project Oncology®
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
- Charles Turck, PharmD, BCPS, BCCCP
- Manali Kamdar, MD
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP